Augmentation of antitumor immunity in regional lymph nodes by local immunotherapy.
We have previously reported that the antitumor effect of OK-432, a streptococcal preparation, is markedly augmented when injected intratumorally together with fibrinogen (OK-432/fbg) [1]. In order to elucidate the effects of this immunotherapy on regional lymph nodes (RLN), we carried out both morphological and functional analyses of the RLN from colonic cancer patients treated with OK-432/fbg. Computer-aided morphometry revealed that the maximal cross-sectional areas and the broadest diameters of the RLN were significantly greater (p < 0.01) in patients who had undergone local immunotherapy than in patients who had not. The component structures of RLN, such as sinus, follicle and paracortex, were all enlarged in the OK-432/fbg-treated patients, and necrosis of metastatic tumors was observed. RLN lymphocytes recovered from OK-432/fbg treated patients showed elevated reactivity to phytohemagglutinin (PHA) and the stimulation index was clearly higher than that of control patients. Flow cytometric analysis revealed a predominance of T-cells, especially CD4 subsets, and higher positivity for both CD25 and HLA-DR. Furthermore, RLN lymphocytes killed more effectively K562 and Daudi cells in the patients who had had immunotherapy. These results suggest that the effect of local immunotherapy with OK-432/fbg is not restricted to the site of injection but extends to the lymph nodes, and contributes to tumor regression through the augmentation of cellular immunity.
Sakita
I
I
Department of Surgery II, Osaka University Medical School, Japan.
Monden
T
T
Nagaoka
H
H
Katsumoto
Y
Y
Wakasugi
T
T
Tomita
N
N
Takeda
T
T
Kobayashi
T
T
Shimano
T
T
Mori
T
T
D000368:Aged; D003110:Colonic Neoplasms / Q000276:immunology* / Q000601:surgery / Q000628:therapy*; D003131:Combined Modality Therapy; D005260:Female; D005340:Fibrinogen / Q000627:therapeutic use*; D005434:Flow Cytometry; D006801:Humans; D015979:Killer Cells, Lymphokine-Activated / Q000187:drug effects / Q000276:immunology; D007694:Killer Cells, Natural / Q000187:drug effects / Q000276:immunology; D008198:Lymph Nodes / Q000187:drug effects / Q000276:immunology*; D008213:Lymphocyte Activation / Q000187:drug effects; D008214:Lymphocytes / Q000276:immunology / Q000502:physiology; D008297:Male; D008875:Middle Aged; D010641:Phenotype; D010844:Picibanil / Q000627:therapeutic use*
D010844:Picibanil; D005340:Fibrinogen